You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
University of Glasgow spinout Gabriel Precision Oncology will contribute a bioinformatics pipeline derived from cancer tissue samples to accelerate MDx adoption.
Genosity will combine its Integrated Genomic Toolkit with Israel-based Igentify's genetic counseling software, which both firms will comarket.
PierianDx will integrate its cancer profiling assays with Pillar Biosciences' PiVAT bioinformatics pipeline on a GPDR-compliant platform.
French startup SeqOne has adapted its sequencing data-analysis platform to support a new method for high-throughput processing of coronavirus tests in its home country.
The company has issued a call for the 2,500 independent MDx labs across the US to join together in an effort to double SARS-CoV-2 testing capacity.
Startup BioLizard will develop the algorithm to help Novigenix migrate its immuno-transcriptiomic assay for early colorectal cancer detection to a new NGS-based platform.
Israel-based software company Medial EarlySign will work with Geisinger's innovation center to develop technologies to predict lower GI and other "high-burden" diseases.
Symbolized by its first time exhibiting at HIMSS, Roche Diagnostics is using data to bridge the worlds of imaging, sequencing, diagnostics, drug discovery, and treatment.
City of Hope and Texas Oncology are the first customers for Trapelo, a decision support platform from Innovation Insights that involves labs and payors.
The Series E financing will go, in part, toward expansion of the company's US presence by growing its workforce and marketing to more American hospitals.